市場調查報告書
商品編碼
1467906
2024-2032 年按類型、用途、最終用戶和地區分類的乳房病變定位方法市場報告Breast Lesion Localization Methods Market Report by Type, Usage, End User, and Region 2024-2032 |
IMARC Group年,全球乳房病變定位方法市場規模達12.142億美元。
乳房病變定位方法是指用於檢測因疾病或損傷引起的乳房組織異常變化(也稱為乳房病變)的各種程序。一些常用的方法包括線定位、碳標記、無線電導引隱匿性病變定位 (ROLL)、放射性種子定位 (RSL)、磁性種子定位 (Magseed) 和術中超音波 (IOUS)。這些技術可幫助醫生和醫療保健專業人員做出明智的決定並確定患者的理想治療或手術。隨著外科、影像和生物醫學技術的進步,乳房病變定位方法已經顯著發展,目前正在推動醫療保健領域的需求。
由於生活方式的改變和不健康的飲食,乳癌病例顯著增加是推動市場成長的主要因素。除此之外,越來越多的患者需要進行腫塊切除術和手術活體組織切片,這增加了對乳房病灶定位方法的需求,以確保準確切除目標病灶。此外,各國管理機構正在採取有利舉措,以提高人們對早期發現乳癌益處的認知。例如,澳洲政府啟動了BreastScreen Australia,這是一項全國性乳癌篩檢計劃,每兩年為50-74歲的女性提供免費乳房X光檢查。再加上越來越多的政府和私人對乳癌診斷、活體組織切片和其他相關醫療程序的報銷政策以及領先企業推出的創新乳房病變定位設備,正在促進市場成長。此外,對研發(R&D)活動的大量投資為市場參與者提供了利潤豐厚的機會。其他因素,包括接受豐胸等整容手術的人數不斷增加、醫療保健基礎設施改善、技術進步以及消費者醫療保健支出增加,也創造了積極的市場前景。
The global breast lesion localization methods market size reached US$ 1,214.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,656.8 Million by 2032, exhibiting a growth rate (CAGR) of 8.9% during 2024-2032.
Breast lesion localization methods refer to various procedures employed to detect abnormal changes in the breast tissue, also called a breast lesion, caused due to a disease or injury. Some commonly used methods include wire localization, carbon marking, radio-guided occult lesion localization (ROLL), radioactive seed localization (RSL), magnetic seed localization (Magseed), and intraoperative ultrasound (IOUS). These techniques assist doctors and healthcare professionals in making informed decisions and determining the ideal treatment or surgery for the patient. With advancements in surgical, imaging and biomedical technology, breast lesion localization methods have significantly evolved, which is presently driving their demand in the healthcare sector.
A significant increase in breast cancer cases due to changing lifestyles, and unhealthy diets represents the primary factor driving the market growth. Besides this, the growing number of patients requiring lumpectomy and surgical biopsy procedures is augmenting the demand for breast lesion localization methods to ensure accurate removal of the target lesion. Additionally, the governing agencies of various countries are taking favorable initiatives to spread awareness regarding the benefits of early detection of breast cancer. For instance, the Government of Australia launched BreastScreen Australia, a national breast cancer screening program that provides a free mammogram to women aged 50-74 every two years. This, in confluence with the increasing number of government and private reimbursement policies for breast cancer diagnosis, biopsy and other related medical procedures and the launch of innovative breast lesion localization devices by leading players, is catalyzing the market growth. Furthermore, heavy investments in research and development (R&D) activities are offering lucrative opportunities to the market players. Other factors, including the rising number of individuals undergoing cosmetic surgeries like breast enhancement, improving healthcare infrastructure, technological advancements, and increasing consumer healthcare spending, are also creating a positive market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global breast lesion localization methods market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type, usage and end user.
Wire Localization
Radioisotope Localization
Magnetic Tracers Localization
Others
Tumor Identification
Sentinel Lymph Node Identification
Lumpectomy
Mastectomy
Hospitals
Diagnostic Centres
Oncology Clinics
Ambulatory Surgical Centers
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Argon Medical Devices Inc., Becton Dickinson and Company, Cook Group Incorporated, CP Medical Inc. (Theragenics Corporation), Endomagnetics Ltd., Hologic Inc., IsoAid LLC, IZI Medical Products (Landauer Inc), Laurane Medical LLC, Leica Biosystems Nussloch GmbH (Danaher Corporation), Merit Medical Systems Inc. and Sterylab S.r.l.